Trial Profile
Molecular Analysis for Therapy Choice (MATCH)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2025
Price :
$35
*
At a glance
- Drugs ABSK 091 (Primary) ; Adavosertib (Primary) ; Afatinib (Primary) ; Binimetinib (Primary) ; Capivasertib (Primary) ; Copanlisib (Primary) ; Crizotinib (Primary) ; Dabrafenib (Primary) ; Dasatinib (Primary) ; Defactinib (Primary) ; Erdafitinib (Primary) ; GSK 2636771 (Primary) ; Ipatasertib (Primary) ; Larotrectinib (Primary) ; Nivolumab (Primary) ; Osimertinib (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Sapanisertib (Primary) ; Sunitinib (Primary) ; Taselisib (Primary) ; Trametinib (Primary) ; Trastuzumab emtansine (Primary) ; Ulixertinib (Primary) ; Vismodegib (Primary)
- Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Anal cancer; Bladder cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; CNS cancer; Colorectal cancer; Endometrial cancer; Gastrointestinal cancer; Glioblastoma; Gliosarcoma; Haemangiosarcoma; Head and neck cancer; Leiomyosarcoma; Liver cancer; Lung cancer; Lymphoma; Malignant melanoma; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Perivascular epithelioid cell tumours; Prostate cancer; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer; Triple negative breast cancer; Urogenital cancer; Uterine cancer
- Focus Registrational; Therapeutic Use
- Acronyms MATCH; NCI-MATCH; NCI-MATCH ECOG-ACRIN Trial (EAY131)
Most Recent Events
- 01 Oct 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
- 01 Oct 2025 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2026.
- 04 Jun 2024 Results(n=200) reporting the molecular profiles of ctDNA from a subset of the NCI-MATCH screened patients with gynecologic cancers, presented at the 60th Annual Meeting of the American Society of Clinical Oncology